17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study

American Journal of Obstetrics and Gynecology

Volumn 216, Issue 6, 2017, Pages 600.e1-600.e9

  Nelson, David B ^a   McIntire, Donald D ^a   McDonald, Jeffrey ^a   Gard, John ^b   Turrichi, Paula ^b   Leveno, Kenneth J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

Author keywords

efficacy; external validity; gestational diabetes; neonatal morbidity; prematurity; preterm birth; progesterone; progestogen; randomized trial

Indexed keywords

HYDROXYPROGESTERONE CAPROATE; 17-ALPHA-HYDROXY-PROGESTERONE CAPROATE; GESTAGEN; PROGESTERONE DERIVATIVE;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OBSTETRIC DELIVERY; PREGNANCY DIABETES MELLITUS; PREMATURE LABOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; RISK REDUCTION; TREATMENT OUTCOME; BLOOD; CHEMICALLY INDUCED; DIABETES, GESTATIONAL; GESTATIONAL AGE; PREGNANCY; PREMATURE BIRTH; RECURRENT DISEASE;

ADULT; COHORT STUDIES; DIABETES, GESTATIONAL; FEMALE; GESTATIONAL AGE; HUMANS; HYDROXYPROGESTERONES; PREGNANCY; PREMATURE BIRTH; PROGESTINS; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 85016729411     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2017.02.025     Document Type: Article

References (58)

1. Institute of Medicine. Preterm birth: causes, consequences, and prevention. 2007, National Academies Press, Washington (DC).
2. Manuck, T.A., Sheng, X., Yoder, B.A., Varner, M.W., Correlation between initial neonatal and early childhood outcomes following preterm birth. Am J Obstet Gynecol 210 (2014), 426.e1–426.e9.
3. Meis, P.J., Klebanoff, M., Thom, E., et al. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 348 (2003), 2379–2385.
4. da Fonseca, E.B., Bittar, R.E., Carvalho, M.H., Zagaib, M., Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 188 (2003), 419–424.
5. O'Brien, J.M., Adair, C.D., Lewis, D.F., et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Gynecol 30 (2007), 687–696.
6. Fonseca, E.B., Celik, E., Parra, M., Singh, M., Nicolaides, K.H., Progesterone and the risk of preterm birth among women with a short cervix. Fetal Medicine Foundation Second Trimester Screening Group. N Engl J Med 357 (2007), 462–469.
7. Hassan, S.S., Romero, R., Vidyadhari, D., et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. PREGNANT Trial. Ultrasound Obstet Gynecol 38 (2011), 18–31.
8. Romero, R., Nicolaides, K., Conde-Agudelo, A., et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol 206 (2012), 124.e1–124.e9.
9. Romero, R., Nicolaides, K.H., Conde-Agudelo, A., et al. Vaginal progesterone decreases preterm birth ≤34 weeks of gestation in women with a singleton pregnancy and a short cervix: an updated meta-analysis including data from the OPPTMUM study. Ultrasound Obstet Gynecol 48 (2016), 308–317.
10. FDA. FDA approves drug to reduce risk of preterm birth in at-risk pregnancy women. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm242234.htm. Accessed Feb. 4, 2011.
11. American College of Obstetricians and Gynecologists. Prediction and prevention of preterm birth. Practice bulletin no. 130. Obstet Gynecol 120 (2012), 964–973.
12. Society for Maternal-Fetal Medicine Publications Committee, with the assistance of Vincenzo Berghella, MD. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. Am J Obstet Gynecol 206 (2012), 376–386.
13. SMFM Publications Committee. SMFM statement: the choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth. Am J Obstet Gynecol 216 (2017), B11–B13.
14. Romero, R., Yeo, L., Miranda, J., Hassan, S., Conde-Agudelo, A., Chaiworapongsa, T., A blueprint for the prevention of preterm birth: vaginal progesterone in women with a short cervix. J Perinat Med 41 (2013), 27–44.
15. Clinical Trials. Confirmatory study of 17P versus vehicle for the prevention of preterm birth in women with a previous singleton spontaneous preterm delivery (PROLONG). Available at: https://clinicaltrials.gov/ct2/show/NCT01004029. Accessed January 6, 2017.
16. Booth, C.M., Tannock, I.F., Randomized controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer 110 (2014), 551–555.
17. Sherman, R.E., Anderson, S.A., Dal Pan, G.J., et al. Real-world evidence–what is it and what can it tell us?. N Engl J Med 375 (2016), 2293–2297.
18. Chang, J., Zhao, Y., Zhao, W., et al. Quality assessment of compounded 17-hydroxyprogesterone caproate. Am J Obstet Gynecol 210 (2014), 47.e1–47.e7.
19. McManemy, J., Cooke, E., Amon, E., Leet, T., Recurrence risk for preterm delivery. Am J Obstet Gynecol 196 (2007), 576.e1–576.e7.
20. Caritis, S.N., Venkataramanan, R., Thom, E., et al. Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth. Am J Obstet Gynecol 210 (2014), 128.e1–128.e6.
21. Manuck, T.A., Esplin, M.S., Biggio, J., et al. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth. Am J Obstet Gynecol 214 (2016), 376.e1–376.e8.
22. Bloom, S.L., Yost, N.P., McIntire, D.D., Leveno, K.L., Recurrence of preterm birth in singleton and twin pregnancies. Obstet Gynecol 98 (2001), 379–385.
23. Johnson, J.W., Austin, K.L., Jones, G.S., Davis, G.H., King, T.M., Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med 293 (1975), 675–680.
24. Hauth, J.C., Gilstrap, L.C. III, Brekken, A.L., Hauth, J.M., The effect of 17 alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population. Am J Obstet Gynecol 146 (1983), 187–190.
25. Keirse, M.J., Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynecol 97 (1990), 149–154.
26. FDA. Gestiva slides revision. Meeting of the Advisory Committee for Reproductive Health Drugs. Aug. 29, 2006. NDA 21-945, 17α-hydroxyprogesterone caproate (Gestiva). Available at: http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4227S1-02-03-FDA_Wesley_files/frame.htm. Accessed Jan. 7, 2017.
27. Romero, R., Stanczyk, F.Z., Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice. Am J Obstet Gynecol 208 (2013), 421–426.
28. O'Brien, J.M., Lewis, D.F., Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety. Am J Obstet Gynecol 214 (2016), 45–56.
29. Keirse, M.J., Progesterone and preterm: seventy years of “déjà vu” or “still to be seen”?. Birth 31 (2004), 230–235.
30. Brancazio, L.R., Murtha, A.P., Heine, R.P., Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 349 (2003), 1087–1088.
31. O'Sullivan, M.D., Hehir, M.P., O'Brien, Y.M., et al. 17 alpha-Hydroxyprogesterone caproate vehicle, castor oil, enhances the contractile effect of oxytocin in human myometrium in pregnancy. Am J Obstet Gynecol 202 (2010), 453.e1–453.e4.
32. Carr, D.B., Gabbe, S., Gestational diabetes: detection, management, and implications. Clin Diab 16 (1998), 4–11.
33. Rebarber, A., Istwan, N.B., Russo-Stieglitz, K., et al. Increased incidence of gestational diabetes in women receiving prophylactic 17α-hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Diabetes Care 30 (2007), 2277–2280.
34. Csapo, A.I., Pinto-Dantas, C.A., The effect of progesterone on the human uterus. Proc Natl Acad Sci U S A 54 (1965), 1069–1076.
35. Saito, Y., Sakamoto, H., MacLusky, N.J., Naftolin, F., Gap junctions and myometrial steroid hormone receptors in pregnant and postpartum rats: a possible cellular basis for the progesterone withdrawal hypothesis. Am J Obstet Gynecol 151 (1985), 805–812.
36. Mesiano, S., Myometrial progesterone responsiveness and the control of human parturition. J Soc Gynecol Investig 11 (2004), 193–202.
37. Zakar, T., Mesiano, S., How does progesterone relax the uterus in pregnancy?. N Engl J Med 364 (2011), 972–973.
38. Garfield, R.E., Shi, L., Shi, S.Q., Use of progesterone and progestin analogs for inhibition of preterm birth and other uterine contractility disorders. Facts Views Vis Obgyn 4 (2012), 237–244.
39. Ito, A., Imada, K., Sato, T., Kubo, T., Matsushima, K., Mori, Y., Suppression of interleukin 8 production by progesterone in rabbit uterine cervix. Biochem J 301 (1994), 183–186.
40. Imada, K., Ito, A., Sato, T., Namiki, M., Nagase, H., Mori, Y., Hormonal regulation of matrix metalloproteinase 9/gelatinase B gene expression in rabbit uterine cervical fibroblasts. Biol Reprod 56 (1997), 575–580.
41. Yellon, S.M., Ebner, C.A., Elovitz, M.A., Medroxyprogesterone acetate modulates remodeling, immune cell census, and nerve fibers in the cervix of a mouse model for inflammation-induced preterm birth. Reprod Sci 16 (2009), 257–264.
42. Fukuyama, A., Tanaka, K., Kakizaki, I., et al. Anti-inflammatory effect of proteoglycan and progesterone on human uterine cervical fibroblasts. Life Sci 90 (2012), 484–488.
43. Furcron, A.-E., Romero, R., Plazyo, O., et al. Vaginal progesterone, but not 17α-hydroxyprogesterone caproate, has anti-inflammatory effects at the murine maternal-fetal interface. Am J Obstet Gynecol 213 (2015), 846.e1–846.e19.
44. Nold, C., Maubert, M., Anton, L., et al. Prevention of preterm birth by progestational agents: what are the molecular mechanisms?. Am J Obstet Gynecol 208 (2013), 223.e1–223.e7.
45. Elovitz, M.A., Mrinalini, C., The use of progestational agents for preterm birth: lessons from a mouse model. Am J Obstet Gynecol 195 (2006), 1004–1010.
46. Manuck, T.A., Lai, Y., Meis, P.J., et al. Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 205 (2011), 135.e1–135.e9.
47. Manuck, T.A., Watkins, W.S., Moore, B., et al. Pharacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention. Am J Obstet Gynecol 210 (2014), 321.e1–321.e21.
48. Cohen, A.W., Copel, J.A., Macones, G.A., Menard, M.K., Riley, L., Saade, G.R., Unjustified increase in cost of care resulting from US Food and Drug Administration approval of Makena (17α-hydroxyprogesterone caproate). Obstet Gynecol 117 (2011), 1408–1412.
49. Petrini, J.R., Callaghan, W.M., Klebanoof, M., et al. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol 105 (2005), 267–272.
50. Stanley, K., Design of randomized controlled trials. Circulation 115 (2007), 1164–1169.
51. Clinical Trials. FAQ: clinical trial phases. Available at: https://www.nlm.nih.gov/services/ctphases.html. Accessed January 8, 2017.
52. Bradford Hill, A., The environment and disease: association or causation?. Proc R Soc Med 58 (1965), 295–300.
53. Ioannidis, J.P., Exposure-wide epidemiology: revisiting Bradford Hill. Stat Med 35 (2016), 1749–1762.
54. Nallamothu, B.K., Hayward, R.A., Bates, E.R., Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation 118 (2008), 1294–1303.
55. Althabe, F., Belizán, J.M., McClure, E.M., et al. A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries: the ACT cluster-randomized trial. Lancet 385 (2015), 629–639.
56. Roberts, D., Dalziel, S., Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev, 3, 2006, CD004454.
57. SMFM Newsroom. Physicians weigh in on study in The Lancet on use of antenatal corticosteroids in prevention of pre-term birth. Available at: http://www.smfmnewsroom.org/2014/10/physicians-weigh-in-on-study-in-the-lancet-on-use-of-antenatal-corticosteroids-in-prevention-of-pre-term-birth/. Accessed January 8, 2016.
58. Mcclure E, Goldenberg R, Swanson D, et al. Routine antenatal ultrasound in low/middle income countries: a cluster randomized trial. Abstract no. 3. Presented at: Society for Maternal-Fetal Medicine 37th Annual Meeting–The Pregnancy Meeting; Jan. 23-28, 2017; Las Vegas, NV.